Zobrazeno 241 - 250
of 1 053
pro vyhledávání: '"Hiroshi Handa"'
Autor:
Takumi Ito, Hiroshi Handa
Publikováno v:
International Journal of Hematology. 104:293-299
Thalidomide was first developed as a sedative around 60 years ago, but exhibited teratogenicity, leading to serious defects such as limb deformities. Nevertheless, thalidomide is now recognized as a therapeutic drug for the treatment of Hansen's dise
Autor:
Norifumi Tsukamoto, Hirokazu Murakami, Tetsuhiro Kasamatsu, Akihiko Yokohama, Rumi Ino, Morio Matsumoto, Takayuki Saitoh, Morio Sawamura, Hiroshi Handa, Hiroaki Shimizu, Nanami Gotoh, Takeki Mitsui
Publikováno v:
Hematological Oncology. 35:711-718
Interleukin-10 (IL-10) and IL-10 receptor (IL-10R) single nucleotide polymorphisms have been implicated in the pathogenesis of many cancers. We investigated the influence of IL-10 -592C/A, IL-10RA I224V, and IL-10RB K47E on the risk of developing mul
Autor:
Alexander L. Ruchelman, Jack Houston, Nai-Yu Wang, Lyn'Al Nosaka, Antonia Lopez-Girona, Takumi Ito, Gilles Carmel, Mary E Matyskiela, Wei Fang, Derek Nguyen, Philip P Chamberlain, Thomas O. Daniel, Karen Miller, Chin-Chun Lu, Barbra Pagarigan, Svetlana Gaidarova, Gang Lu, Shuichan Xu, James Carmichael, Tam Tran, Gabriel C. Lander, Mariko Riley, Brian E. Cathers, Hiroshi Handa
Publikováno v:
Nature. 535:252-257
Immunomodulatory drugs bind to cereblon (CRBN) to confer differentiated substrate specificity on the CRL4(CRBN) E3 ubiquitin ligase. Here we report the identification of a new cereblon modulator, CC-885, with potent anti-tumour activity. The anti-tum
Autor:
Hajime Yoshifuji, Taira Maekawa, Koichiro Ohmura, Hiroshi Handa, Hiroto Kojima, Kimiko Yurugi, Hiroh Saji, Tsuneyo Mimori, Yoshihisa Yamano, Fumihiko Matsuda, Yasuo Miura, Chikashi Terao
Publikováno v:
Rheumatology. 55:1686-1692
Objective To uncover the genetic background of relapsing polychondritis (RPC), a rare autoimmune disease with unknown mechanisms characterized by systemic inflammation of the cartilage, to deepen our understanding of the pathophysiology of RPC and sh
Autor:
Yoshihisa Nojima, Hiroshi Handa, Hiroyuki Noguchi, Takuma Ishizaki, Takeki Mitsui, Yoshiyuki Ogawa, Masahiro Mihara, Hiroaki Shimizu, Kunio Yanagisawa
Publikováno v:
The Kitakanto Medical Journal. 66:211-215
Autor:
Hiroshi Handa
Publikováno v:
Nihon Naika Gakkai Zasshi. 105:1202-1208
Autor:
Arito Yamane, Atsushi Isoda, Takayuki Maruhashi, Natsumi Nishimoto, Kozue Susa, Reina Ishikawa, Hiroshi Handa, Tomomi Sekigami, Kohtaro Toyama, Takeki Mitsui, Masamitsu Karasawa, Akihiko Yokohama, Makiko Takizawa, Yoko Hashimoto, Hidemi Ogura, Hirono Iriuchijima, Takahiro Jimbo
Publikováno v:
Japanese Journal of Transfusion and Cell Therapy. 62:552-559
Autor:
Hiroyuki Noguchi, Yoshihisa Nojima, Chiaki Naito, Yoshiyuki Ogawa, Hiroaki Shimizu, Masahiro Mihara, Kunio Yanagisawa, Takeki Mitsui, Hiroshi Handa, Takuma Ishizaki
Publikováno v:
The Kitakanto Medical Journal. 66:149-154
Autor:
Satoshi Ōmura, Masaki Hiramoto, Xiao-Fang Che, Shota Moriya, Toshiaki Sunazuka, Akihiro Sugawara, Satoshi Sakamoto, Hiroko Kokuba, Hiromi Kazama, Takao Itoi, Tomohisa Yokoyama, Keisuke Miyazawa, Shuntaro Mukai, Hiroshi Handa
Publikováno v:
International Journal of Oncology
Pancreatic cancer is one of the most difficult types of cancer to treat because of its high mortality rate due to chemotherapy resistance. We previously reported that combined treatment with gefitinib (GEF) and clarithromycin (CAM) results in enhance
Autor:
Fumihiko Nakamura, Morio Matsumoto, Takayuki Saitoh, Kayoko Murayama, Go Yamamoto, Eiichi Nagura, Hiroshi Handa, Kazuyuki Shimizu, Shuji Ozaki, Hirono Iriuchishima, Yoshihisa Nojima, Hirokazu Murakami, Jun Konishi
Publikováno v:
Acta Haematologica. 135:113-121
We investigated the treatment and outcome of Japanese patients with primary plasma cell leukemia (pPCL) in the era of novel agents and analyzed the risk factors affecting survival. Among 3,318 patients with symptomatic multiple myeloma (MM), 38 patie